Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has received regulatory clearance from the FDA to proceed with the pediatric expansion of its Phase I clinical trial for HG-CT-1, a CAR-T therapy for relapsed/refractory acute myeloid leukemia. This milestone allows the company to initiate pediatric enrolment, broadening the impact and value of HG-CT-1 and reinforcing the company’s commitment to innovative therapies and strategic growth.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 30,400
Technical Sentiment Signal: Sell
Current Market Cap: £8.15M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.